文献速递腹部技术与安全PETCT

对比增强18F-FDG PET/CT在肝细胞癌桥接治疗后甲胎蛋白升高的等待肝移植患者中的效能

Efficacy of contrast-enhanced FDG PET/CT in patients awaiting liver transplantation with rising alpha-fetoprotein after bridge therapy of hepatocellular carcinoma.
PubMed 文献 · Eur Radiol · 2018-06-12

这项前瞻性研究纳入100例接受肝细胞癌局部区域治疗后等待肝移植、随访中甲胎蛋白升高的患者,均行对比增强18F-FDG PET/CT检查。以组织病理学和临床影像随访为参考标准,该检查检出肿瘤复发的敏感度92.8%、特异度94.1%、准确率93%,甲胎蛋白水平与肿瘤/正常肝SUVmax比值显著相关(r=0.2283;p=0.0224),PET阳性最佳阈值为>1.21。

要点

  • 对比增强18F-FDG PET/CT检出肝细胞癌复发的敏感度92.8%、特异度94.1%、准确率93%。
  • 78例检出肿瘤复发:肝内病灶13例、肝外转移10例、肝内合并肝外病灶55例。
  • 甲胎蛋白水平与肿瘤/正常肝SUVmax比值显著相关(r=0.2283;p=0.0224),PET阳性最佳阈值为>1.21。

核心结论

  • 对比增强18F-FDG PET/CT是检出肝细胞癌局部区域治疗后甲胎蛋白升高患者肝内复发或肝外转移的有价值工具,应纳入等待肝移植的常规评估。

研究设计与样本

  • 前瞻性研究,纳入100例等待肝移植且既往接受肝细胞癌局部区域治疗、随访中甲胎蛋白升高的患者,均行对比增强18F-FDG PET/CT,以组织病理学和临床及影像随访为参考标准。

关键影像表现/征象

  • 对比增强18F-FDG PET/CT检出78例肿瘤复发,其中肝内病灶13例、肝外转移10例、肝内合并肝外病灶55例。
  • 计算每例患者肿瘤的SUVmax及肿瘤SUVmax与正常肝SUVmax的比值。

诊断标准与关键数值

  • 对比增强18F-FDG PET/CT检出肝细胞癌复发的敏感度92.8%、特异度94.1%、准确率93%。
  • 18F-FDG PET阳性最佳阈值为肿瘤/正常肝SUVmax比值>1.21。
  • 甲胎蛋白与肿瘤/正常肝SUVmax比值显著相关(r=0.2283;p=0.0224)。
  • 甲胎蛋白的理想截断值为>202。

临床应用与阅片要点

  • 对肝细胞癌局部区域治疗后甲胎蛋白升高、等待肝移植的患者,对比增强18F-FDG PET/CT可用于检出肝内复发或肝外转移。
  • 作者认为对比增强18F-FDG PET/CT应纳入等待肝移植的常规评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To assess the diagnostic accuracy and illustrate positive findings of contrast-enhanced fluorine-18 fluoro-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) image in patients awaiting liver transplantation (LT) with rising alpha-fetoprotein (AFP) after bridge therapy of hepatocellular carcinoma (HCC).

MATERIALS AND METHODS: This prospective study included 100 patients who were waiting for LT and who previously underwent locoregional therapy (LRT) of HCC. These patients had rising AFP levels on a routine follow-up examination awaiting LT. All patients underwent a contrast-enhanced 18F-FDG PET/CT examination. We calculated for each patient the maximum standardised uptake value (SUVmax) of the tumour and the ratio of the tumoral SUVmax to the normal-liver SUVmax. The diagnostic accuracy and positive contrast-enhanced findings of 18F-FDG PET/CT were established by histopathology and clinical and imaging follow-up as the reference standards.

RESULTS: Contrast-enhanced 18F-FDG PET/CT detected tumour relapse in 78 patients (13 patients had intrahepatic lesions, 10 patients had extrahepatic metastases and 55 patients with combined lesions). The sensitivity, specificity and accuracy values of contrast-enhanced 18F-FDG PET/CT examination in the detection of HCC recurrence were 92.8%, 94.1% and 93%, respectively. A significant correlation was found between the AFP level and SUVmax ratio (r = 0.2283; p = 0.0224). The best threshold for 18F-FDG PET positivity was >1.21.

CONCLUSION: Contrast-enhanced 18F-FDG PET/CT is a valuable tool for the detection of intrahepatic HCC recurrence or extrahepatic metastasis following rising AFP levels after LRT of HCC, and should be incorporated during routine workup awaiting LT.

KEY POINTS: • 18F-FDG PET/CT is a valuable tool for the detection of HCC recurrence • 18 F-FDG PET/CT should be incorporated during routine workup awaiting liver transplantation • Significant correlation was found between AFP level and SUVmax ratio • The best threshold for 18 F-FDG PET positivity was >1.21 • The ideal cut-off value for AFP was >202.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Refaat R, Basha MAA, Hassan MS, et al. Efficacy of contrast-enhanced FDG PET/CT in patients awaiting liver transplantation with rising alpha-fetoprotein after bridge therapy of hepatocellular carcinoma. Eur Radiol. 2018. PMID: 29948070. doi:10.1007/s00330-018-5425-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。